Get the Stockscreener App
3.525
53.59%
1.23
Jaguar Health Inc stock is traded at $3.525, with a volume of 863.06K.
It is up +53.59% in the last 24 hours and up +101.80% over the past month.
Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
See More
Previous Close:
$2.295
Open:
$3.32
24h Volume:
863.06K
Relative Volume:
0.08
Market Cap:
$6.86M
Revenue:
$29.57M
Net Income/Loss:
$-34.68M
P/E Ratio:
-0.00497
EPS:
-708.7214
Net Cash Flow:
$-7.58M
1W Performance:
+47.18%
1M Performance:
+101.80%
6M Performance:
-96.76%
1Y Performance:
-99.30%
1-Day Range:
$3.25
$4.20
1-Week Range:
$1.865
$4.20
52-Week Range:
$1.175
$548.86
Jaguar Health Inc Stock (JAGX) Company Profile
Name
Jaguar Health Inc
Sector
Industry
Phone
415-371-8300
Address
200 PINE STREET SUITE 400, SAN FRANCISCO, CA
Compare JAGX vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JAGX
Jaguar Health Inc
|
3.525 | 6.86M | 29.57M | -34.68M | -7.58M | -708.72 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Jaguar Health Inc Stock (JAGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-07-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-11-17 | Initiated | Rodman & Renshaw | Buy |
Jaguar Health Inc Stock (JAGX) Latest News
Jaguar Health sets ex-dividend date for special stock dividend - Investing.com
Jaguar Health (JAGX) Announces Special Stock Dividend Ahead of O - GuruFocus
Jaguar Health Provides Update Regarding Special Stock Dividend - ACCESS Newswire
Jaguar Health sets ex-dividend date for Series R preferred stock dividend - StreetInsider
Jaguar Health's Napo Pharmaceuticals Reports Preliminary Data on Crofelemer for Short Bowel Syndrome (JAGX) - GuruFocus
Jaguar Health unit reports crofelemer study results in bowel syndrome - Investing.com
Jaguar Health unit presents crofelemer SBS-IF study data at ACG 2026 - StreetInsider
Jaguar Health, Inc. (JAGX) Posts Preliminary Positive SBS-IF Data - TradingView
Positive Preliminary Results Presented at Annual American College of Gastroenterology Meeting for Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer - Yahoo Finance
Reminder: Today, October 13, 2026, is the Record Date for Jaguar Health's Special Stock Dividend - Lelezard
Jaguar Health, Inc. (JAGX) Sets Record Date for Special Stock Dividend - TradingView
Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Intestinal Failure Panel Discussion at Pediatric Gastroenterology Conference in Abu Dhabi - ACCESS Newswire
Jaguar Health Inc Stock Operating Data - GuruFocus
Jaguar Health Inc (FRA:1JA2) Stock Earnings Transcripts - GuruFocus
Jaguar Health Targets Mid-2027 MVID NDA Filing as Crofelemer Intestinal Failure Program Advances - Yahoo Finance
JAGX Stock Jumps As Rare-Disease Pipeline And Special Dividend Draw Traders - Timothy Sykes
A panel will discuss the gut lining beyond nutrition delivered through a vein on Oct. 30. - Stock Titan
JAGX Stock Draws Traders As Rare-Disease Momentum Builds - StocksToTrade
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
JAGX Stock Draws Trader Focus On Crofelemer Progress, Special Dividend - Timothy Sykes
JAGX Stock Draws Traders As Rare-Disease Pipeline Advances - StocksToTrade
Jaguar Health stock gains after special dividend decision - AD HOC NEWS
Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Intestinal Failure Panel Discussion at Pediatric Gastroenterology Conference in Abu Dhabi - Yahoo Finance
Jaguar Health (JAGX) Stock Climbs Over 34% After-Hours: What's Going On? - Benzinga
Jaguar Health Reports Approval of All Proposals at August 2025 Annual Meeting of Stockholders - Salinas Californian
Jaguar Health (JAGX) Declares Special Stock Dividend of Series R Convertible Preferred Shares - GuruFocus
Jaguar Health Declares Special Series R Preferred Dividend - TipRanks
Jaguar Health Defers Royalty Payments, Extends $6.22M Note, and Gains Series P Consent - TradingView
Jaguar Health Announces a Special Stock Dividend - Knoxville News Sentinel
Jaguar Health Announces a Special Stock Dividend - ACCESS Newswire
Jaguar Health Announces a Special Stock Dividend - Yahoo Finance
Preliminary Results of Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer Accepted for Presentation at Annual American College of Gastroenterology Meeting - Yahoo Finance
Form 8K Jaguar Health Inc For: 28 September By Investing.com - Investing.com Nigeria
Jaguar Health Exchanges 481,584 Shares to Cut $3.4 Million of 2021 Note With Streeterville - TradingView
JAGX Stock Whipsaws As Jaguar Health Builds Rare-Disease Story - StocksToTrade
Jaguar Health jumps 32% on rare pediatric disea... - pluang.com
Jaguar Health Stock Surges Friday: What's Happening? - Benzinga
Jaguar Health Stock Surges Friday: What's Happening? - Benzinga
The Secret Behind +2,261% Day Spike - Banyan Hill Publishing
JAGX Stock Whipsaws As Crofelemer Pipeline And Neonorm Dog Advance - timothysykes.com
JAGX Stock Whipsaws As Rare-Disease Catalysts Meet Cash Strain - StocksToTrade
JAGX Stock Pops As Jaguar Health Advances Rare-Disease Pipeline - timothysykes.com
Jaguar Health Cuts $1.68M From 2021 Note in Stock Exchange With Streeterville - TradingView
Jaguar Health Soars 32% as Rare-Disease Pipeline News Meets Thin Post-Split Float - Yahoo Finance
A holder reports 189,617 Jaguar Health (JAGX) shares, with some voting power shared. - Stock Titan
Jaguar Health Stock Slides Thursday: What's Happening? - Benzinga
Viking Therapeutics Sinks 15% After Pricing Upsized $500M Offering; Jaguar Health Tumbles 25% - Yahoo Finance
Viking Therapeutics Sinks 15% After Pricing Upsized $500M Offering; Jaguar Health Tumbles 25% - 24/7 Wall St.
Jaguar Animal Health Reduces Debt Through Equity Exchange - TipRanks
Jaguar Health Exchanges 547,898 Shares to Cut 2025 Note Balance by $5.05 Million - TradingView
Jaguar Health Inc Stock (JAGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):